Medicis Announces Intent to Restate Financial Statements. News.
Medicis is the prime unaligned specialty pharmaceutical companions in the United States focusing particularly on the healing of dermatological and discriminating conditions. The Company is dedicated to plateful patients attain a fine fettle and youthful appearance and self-image. Medicis has influential branded preparation Products in a number of therapeutic and artistic categories.
The Company's Products have earned completely acceptance by both physicians and patients due to their clinical effectiveness, serious distinction and cosmetic elegance. The Company's Products cover the direction brands RESTYLANE(R) (hyaluronic acid), PERLANE(R) (hyaluronic acid), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), PLEXION(R) (sodium sulfacetamide 10% and sulfur 5%), SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets, TRIAZ(R) (benzoyl peroxide), LIDEX(R) (fluocinonide) Cream 0.05%, VANOS(R) (fluocinonide) Cream 0.1%, and ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) Tablets and Powder and AMMONUL(R) (sodium phenylacetate and sodium benzoate) Injection 10%/10%, drug Products indicated in the Care of Urea Cycle Disorder, and the over-the-counter marque ESOTERICA(R).
For more low-down about Medicis, gladden attack the Company's website at. Forward-Looking Statements This hug put out contains "forward-looking statements" within the substance of Section 21E of the Securities Exchange Act of 1934. All statements included in this Pack issue that hail activities, events or developments that Medicis expects, believes or anticipates will or may materialize in the to be to come are forward-looking statements. These statements count statements on the subject of the results of the Company's revisions to ex aeon pecuniary statements and the Company's estimates of the contact of such revisions on standard quondam periods and the Company's tomorrow fiscal carrying-on in 2008.
There can be no faith that board or the Company's external auditor will not go to conclusions with reference to the results of the restatement that are discrete than management's premonitory estimates or ally additional issues or Other considerations in bond with the restatement and the audit and give one's opinion of process, or that such additional issues or considerations will not lack additional adjustments to the Company's last economic results for additional annual or every three months periods. All of these statements are topic to risks and uncertainties which may cause the statements to be inaccurate. These risks and uncertainties include, but are not fixed to, those resulting from the Company's progressive judgement of the effectiveness of the castigation in the Company's accounting design for sales return reserves; Other accounting adjustments that may issue from consider of our financial statements for the periods in question; the timing of the completing of the audit of our restated monetary statements by our independent auditor; our capability to timely file amended intermittent reports reflecting our restated financial statements; the ramifications of our possible incapability to timely file required reports, including latent delisting of our frequent stock on the NYSE; imminent claims and proceedings relating to such matters, including shareholder suit and fray by the SEC, U.S. Attorney's Office or Other governmental agencies which could outcome in well-mannered or criminal sanctions against the Company and/or unquestionable of our current or former officers, directors and/or employees; and gainsaying c tithe or Other implications for the Company resulting from the accounting adjustments; the factors listed above under Suspension of 2008 Financial Guidance; and Other factors.
Many of these risks and uncertainties are beyond the restraint of Medicis. Several additional risks are outlined in the Company's most up to date annual turn up on Form 10-K for the year ended December 31, 2007, and Other documents we submit with the Securities and Exchange Commission. Forward-looking statements draw the judgment of Medicis' governance as of the lover of this release, and Medicis disclaims any determined or demand to update any forward-looking statements contained herein, which articulate as of the age hereof.
NOTE: Full prescribing report for any Medicis recipe commodity is accessible by contacting the Company. RESTYLANE(R) and PERLANE(R) are trademarks of HA North American Sales AB, a subsidiary of Medicis Pharmaceutical Corporation. All Other marks are the capital of Medicis or its Affiliates.
Originally posted post: read more
Related posts
Tags: company, forward, medicis, statements